NewsBenzingaAltimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December Benzinga 2026.11.05 15:06 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84 As decision model use skyrockets, is customization is the next frontier?